Veritas Aortic Solutions Raises $12M Seed to Take on One of Medicine’s Hardest Problems

Veritas Aortic Solutions has raised $12M in seed funding to advance TVARC (Veritas Transcatheter Valved Aortic Root Conduit), a transcatheter therapy designed for complex diseases involving the aortic root, coronary arteries, and ascending aorta. The Costa Mesa, California-based medical device company emerged from inQB8 Medical Technologies and is focused on developing minimally invasive alternatives for conditions that have historically required open-heart surgery.

The financing was led by a group of experienced MedTech angel investors, with participation from Cedars-Sinai Intellectual Property Company and existing investors in inQB8 Medical Technologies. Veritas plans to use the funding to advance TVARC toward first-in-human clinical use. The broader significance extends beyond the financing itself because diseases involving the aortic root and ascending aorta remain among the most challenging areas in cardiovascular intervention, where treatment options have historically been limited and procedural complexity remains high.

The funding reflects continued investor interest in highly specialized medical-device companies addressing difficult clinical problems rather than incremental improvements to established therapies.

What Happened

Most startup funding announcements follow a familiar pattern. Capital arrives. Optimism follows. Everyone politely agrees the future looks bright. Veritas Aortic Solutions is operating in a category where optimism alone does not get you very far.

The Costa Mesa-based medical device company announced a $12M seed round to support development of TVARC, its transcatheter system designed for high-risk aortic root and ascending aortic disease. The financing includes participation from experienced MedTech investors alongside Cedars-Sinai Intellectual Property Company and investors connected to inQB8 Medical Technologies.

At the center of the story is a problem cardiovascular medicine has wrestled with for decades. Treating diseases involving the aortic root and ascending aorta often requires major surgery, and for many patients that remains the standard path because alternatives are limited. The anatomy is unforgiving, the engineering challenges are substantial, and the clinical stakes are immediate.

Veritas believes TVARC can provide a minimally invasive option where few currently exist. According to publicly reported details, TVARC combines a bioprosthetic aortic valve, an ascending aortic graft, proprietary Chameleon Eye coronary perfusion ports designed to help maintain blood flow to the coronary arteries, and a transfemoral delivery system intended to support precise deployment. That is a complicated sentence because it represents a complicated problem.

Why This Matters

Healthcare investors are not known for casually writing checks into categories with long development cycles, significant regulatory hurdles, and complex clinical pathways. That reality makes this funding noteworthy.

The Veritas Aortic Solutions seed round is less interesting as a financing event and more interesting as a signal. Investors with deep medical-device experience appear willing to back a company pursuing one of the most technically demanding areas in cardiovascular intervention. Modern healthcare innovation often gravitates toward efficiency gains, workflow improvements, software platforms, and diagnostics, but building entirely new treatment approaches for difficult anatomical challenges is a different game.

Success requires engineering, clinical expertise, regulatory strategy, physician adoption, manufacturing capability, and years of execution. Missing any one of those pieces can derail progress. The companies that enter these categories are not looking for easy wins. They are trying to solve problems that remain unsolved because solving them is extraordinarily difficult.

Veritas Aortic Solutions is led by J. Brent Ratz, CEO, and Arshad Quadri, CMO, a cardiac surgeon helping guide the company's effort to develop minimally invasive treatment options for complex aortic disease.

Market Context

The cardiovascular device market has experienced enormous advances over the past 2 decades. Transcatheter technologies transformed treatment for many valve-related conditions, allowing procedures that once required open surgery to become accessible through minimally invasive approaches. Entire segments of cardiovascular care evolved as a result.

Yet the aortic root and ascending aorta remain among the most challenging regions in cardiovascular medicine. Large opportunities often emerge where clinical need remains high but technical complexity discourages competition, creating a landscape where demand exists but innovation arrives slowly.

Veritas Aortic Solutions is positioning itself directly within that gap. The company's focus on root and ascending aortic disease places it in a category where successful innovation can create meaningful clinical impact while also establishing strong competitive differentiation.

Investors understand this dynamic. Markets with fewer viable solutions tend to attract attention when credible teams demonstrate a realistic path forward. Future clinical development will ultimately move through pathways governed by agencies such as the U.S. Food and Drug Administration (FDA).

Competitive Landscape

Veritas is not competing against another software dashboard or a slightly improved workflow tool. Its primary benchmark is the existing standard of care, and that distinction matters.

Many healthcare startups compete for market share. Veritas is attempting to expand what is clinically possible. The company's connection to inQB8 Medical Technologies also provides context because venture creation platforms in MedTech often emerge around highly specialized expertise, physician networks, intellectual property, and development experience accumulated over many years.

That foundation can become a meaningful advantage when addressing categories that demand deep domain knowledge. CEO J. Brent Ratz brings extensive medical-device leadership experience, while CMO Arshad Quadri contributes direct clinical expertise as a cardiac surgeon.

In complex medical-device development, experience is not merely helpful. It becomes part of the product.

What This Signals

The Veritas financing reflects a broader shift occurring across healthcare innovation. Capital is increasingly flowing toward companies pursuing high-conviction solutions to narrowly defined but clinically significant problems.

For years, venture markets rewarded scale stories focused on more users, more growth, and bigger categories. Healthcare often operates differently. Sometimes the most valuable opportunities sit inside highly specialized clinical challenges that affect fewer patients but carry enormous consequences.

Investors appear increasingly comfortable backing companies built around precision rather than breadth. Veritas fits that pattern because the company is not trying to solve every cardiovascular problem. It is attempting to address a specific group of conditions where current treatment options remain limited.

That focus may ultimately prove to be one of its greatest strengths.

The Bigger Industry Shift

The future of medical innovation may look less like broad disruption and more like targeted intervention. Advances in cardiovascular medicine, oncology, neurology, and other specialties increasingly emerge from teams willing to spend years addressing a single difficult problem.

That approach lacks the glamour of consumer technology, but it tends to produce meaningful outcomes. Veritas Aortic Solutions now enters the phase where execution matters more than funding announcements as the company uses the $12M financing to advance TVARC toward first-in-human clinical use, a milestone that will provide a clearer picture of the technology's real-world potential.

Funding creates possibilities. Clinical evidence determines whether those possibilities become reality.

Frequently Asked Questions

What is Veritas Aortic Solutions?

Veritas Aortic Solutions is a Costa Mesa, California-based medical device company developing transcatheter therapies for diseases involving the aortic root, coronary arteries, and ascending aorta.

How much funding did Veritas Aortic Solutions raise?

Veritas Aortic Solutions raised $12M in seed funding.

What is TVARC?

TVARC, or Veritas Transcatheter Valved Aortic Root Conduit, is a minimally invasive device being developed to treat complex aortic disease involving the aortic root and ascending aorta. Additional information is available through Veritas Aortic Solutions.

Who invested in Veritas Aortic Solutions?

The round was led by experienced MedTech angel investors and included Cedars-Sinai Intellectual Property Company and existing investors in inQB8 Medical Technologies.

Who is the CEO of Veritas Aortic Solutions?

J. Brent Ratz serves as CEO and co-founder of Veritas Aortic Solutions.

Who is the CMO of Veritas Aortic Solutions?

Arshad Quadri serves as CMO of Veritas Aortic Solutions.

What will the $12M funding be used for?

The company plans to use the funding to continue development of TVARC and advance the technology toward first-in-human clinical use.

What problem is TVARC designed to solve?

TVARC is designed to address complex diseases involving the aortic root and ascending aorta, areas traditionally treated through open-heart surgery. More information about the company's approach can be found at Veritas Aortic Solutions.